Acumen Pharma 8-K: Officer/Director Changes & Comp Arrangements
Ticker: ABOS · Form: 8-K · Filed: Feb 1, 2024 · CIK: 1576885
| Field | Detail |
|---|---|
| Company | Acumen Pharmaceuticals, INC. (ABOS) |
| Form Type | 8-K |
| Filed Date | Feb 1, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: corporate-governance, executive-changes, compensation, 8-K
TL;DR
**Acumen Pharma just filed an 8-K about leadership changes and executive pay.**
AI Summary
Acumen Pharmaceuticals, Inc. filed an 8-K on February 1, 2024, reporting on the departure of directors or certain officers, election of directors, appointment of certain officers, and compensatory arrangements. This filing indicates potential changes in leadership or executive compensation, which could impact the company's strategic direction and operational efficiency. Investors should monitor these changes as they may signal shifts in corporate governance or financial incentives for key personnel, potentially affecting future performance.
Why It Matters
Changes in leadership and compensation structures can significantly influence a company's future strategy and financial health, directly impacting shareholder value.
Risk Assessment
Risk Level: medium — Changes in leadership can introduce uncertainty regarding future company direction and performance, warranting a medium risk assessment.
Analyst Insight
Investors should closely monitor subsequent filings or press releases from Acumen Pharmaceuticals for specific details on the personnel changes and compensation arrangements, as these will provide clearer insights into the company's future direction and potential impact on stock performance.
Key Numbers
- $0.0001 — par value per share of Common Stock (This is the nominal value assigned to each share of Acumen Pharmaceuticals' common stock.)
Key Players & Entities
- Acumen Pharmaceuticals, Inc. (company) — the registrant filing the 8-K
- February 1, 2024 (date) — date of earliest event reported
- Delaware (company) — state of incorporation for Acumen Pharmaceuticals, Inc.
- 001-40551 (dollar_amount) — Commission File Number
- 36-4108129 (dollar_amount) — IRS Employer Identification No.
- 427 Park St., Charlottesville, Virginia 22902 (company) — address of principal executive offices
- 434-297-1000 (dollar_amount) — registrant's telephone number
- Common Stock, $0.0001 par value (company) — title of class of securities registered
- ABOS (company) — trading symbol on Nasdaq Global Select Market
- The Nasdaq Global Select Market (company) — exchange where securities are registered
Forward-Looking Statements
- Acumen Pharmaceuticals will announce specific details regarding the new officers or directors and their compensation packages. (Acumen Pharmaceuticals, Inc.) — medium confidence, target: Q1 2024
FAQ
What is the primary purpose of Acumen Pharmaceuticals, Inc.'s 8-K filing on February 1, 2024?
The primary purpose of Acumen Pharmaceuticals, Inc.'s 8-K filing on February 1, 2024, is to report on the 'Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers' and 'Compensatory Arrangements of Certain Officers', as well as 'Regulation FD Disclosure' and 'Financial Statements and Exhibits'.
What is the trading symbol for Acumen Pharmaceuticals, Inc. on the Nasdaq Global Select Market?
The trading symbol for Acumen Pharmaceuticals, Inc. on The Nasdaq Global Select Market is ABOS, as stated in the filing under 'Securities registered pursuant to Section 12(b) of the Act'.
What is the state of incorporation for Acumen Pharmaceuticals, Inc.?
Acumen Pharmaceuticals, Inc. is incorporated in Delaware, as indicated in the filing under 'State or Other Jurisdiction of Incorporation'.
What is the par value of Acumen Pharmaceuticals, Inc.'s Common Stock?
The par value of Acumen Pharmaceuticals, Inc.'s Common Stock is $0.0001, as specified in the filing under 'Title of each class' for 'Common Stock'.
What is the business address of Acumen Pharmaceuticals, Inc. as reported in the 8-K?
The business address of Acumen Pharmaceuticals, Inc. is 427 Park St., Charlottesville, Virginia 22902, as listed under 'Address of Principal Executive Offices' in the 8-K filing.
Filing Stats: 766 words · 3 min read · ~3 pages · Grade level 11 · Accepted 2024-02-01 07:16:51
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value ABOS The Nasdaq Global Select
Filing Documents
- abos-20240201.htm (8-K) — 29KB
- jimdannouncement13024.htm (EX-99.1) — 6KB
- jimdannouncement13024001.jpg (GRAPHIC) — 238KB
- jimdannouncement13024002.jpg (GRAPHIC) — 167KB
- 0001576885-24-000032.txt ( ) — 725KB
- abos-20240201.xsd (EX-101.SCH) — 2KB
- abos-20240201_lab.xml (EX-101.LAB) — 24KB
- abos-20240201_pre.xml (EX-101.PRE) — 13KB
- abos-20240201_htm.xml (XML) — 3KB
01 Regulation FD
Item 7.01 Regulation FD. On February 1, 2024, the Company issued a press release announcing the appointment of Mr. Doherty as President and Chief Development Officer. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished pursuant to this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filing, except as otherwise expressly stated in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d). Exhibits Exhibit No. Description 99.1 Press Release, dated February 1, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Acumen Pharmaceuticals, Inc. Dated: February 1, 2024 By: /s/ Matthew Zuga Matthew Zuga Chief Financial Officer and Chief Business Officer